11 May, 2022, New York
ICON is proud to sponsor the FT US Pharma and Biotech Summit (New York, May 11th), the focus of which is ‘Driving Investment | Accelerating Innovation | Enhancing Access’ – with discussion on regional and global trends in areas such as drug discovery, clinical development and market access.
The pandemic accelerated innovation in clinical trials, especially in terms of how to connect with patients and investigators. What advances are we seeing in the use of NLP algorithms in clinical trials? What is the potential for tools like digital twins in simulating clinical trials and predicting their success? What other ways are there to achieve faster and better outcomes in clinical trials for patients, investigators, and sponsors?
Chief Medical & Innovation Officer
Dr. Greg Licholai is Chief Medical & Innovation Officer at ICON plc. Dr. Licholai is on faculty of Yale School of Management, Co-Director of the Center for Digital Health and teaches innovating healthcare at Harvard Business School. Previously, Dr. Licholai was President of rare disease at Moderna Therapeutics, President and Chief Medical Officer at Castle Creek Pharmaceuticals, and partner at McKinsey & Co. where he ran the healthcare data service line. Dr. Licholai was also a senior executive at Proteostasis, Amicus Therapeutics and Medtronic Neurological as well as venture investor for Domain Associates. Dr. Licholai was co-founder of Immunome Therapeutics.
Dr. Licholai has degrees from Harvard Business School, Yale School of Medicine, Columbia University and Boston College. Dr. Licholai trained at the Brigham and Women's, Children's, and Massachusetts General Hospitals. Dr. Licholai serves on multiple company and non-profit boards including advisor to the Clinical Trials Transformation Initiative (CTTI), a public private partnership co-founded by Duke University and the Food and Drug Administration (FDA). Dr. Licholai writes about innovation in healthcare for Forbes.
As a lead sponsor, ICON is pleased to offer clients and other third parties, a 25% discount on the registration fee off the full in-person registration price of $999, or digital pass registration of $259